Sunday, October 25, 2026Daily EditionIndependent journalism
BeCrypto NewsIndependent digital asset reporting
Sign in Write
BTC $80,414 +0.17%ETH $2,343.72 +0.28%SOL $101.54 +0.33%XRP $1.30 +0.66%BNB $739.76 +1.16%DOGE $0.0771 +0.10%Prices: CoinGecko,
Back
Markets

Merck and Moderna Report 42% Relative Risk Reduction in Melanoma Trial

By John Kim for TokenPost

Image: TokenPost

The iShares Biotechnology ETF (IBB) had a year-to-date NAV total return of 25.41% as of Oct. 21.

Read the full story on TokenPost

BeCrypto News shows a short excerpt and links to the publisher. The full report belongs to TokenPost.

Latest in Markets

All Markets stories